Consequences of departure of doctors' prescriptions from available evidence;Consequences des ecarts entre les donnees actuelles de la science (DAS) et la pratique medicale

Therapie

Volumn 51, Issue 3, 1996, Pages 225-232

  Boissel, J P ^a  

^a Service de Pharmacologie Clinique   (France)

Author keywords

models; quality of care; therapy utilization studies

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG INFORMATION; HEALTH CARE QUALITY; LIFESPAN; MEDICAL DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; CONTROLLED CLINICAL TRIAL; DRUG UTILIZATION; HUMAN; MEDICAL ETHICS; PROFESSIONAL PRACTICE; SCIENCE; STATISTICS; THEORETICAL MODEL;

CONTROLLED CLINICAL TRIALS; DRUG UTILIZATION; ETHICS, MEDICAL; HUMANS; MODELS, THEORETICAL; PROFESSIONAL PRACTICE; QUALITY OF HEALTH CARE; SCIENCE;

EID: 0029955652     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chalmers TC. The impact of controlled clinical trials on the practice of medicine. Mt Sinai J Med 1974; 41, 753-795.
2. Stross JK, Harlan WR. Dissemination of new medical information. JAMA 1979; 241: 2622-2024.
3. Fineberg HV. Effects of clinical evaluation on the diffusion of medical technology. In: Assessing medical technologies, The Institute of Medicine Ed., Washington DC: National Academy Press, 1985: 176-210.
4. Boissel JP. Impact of controlled clinical trials on the practice of medicine. Controlled Clin Trials 1989; 10: 120S-134S.
5. Furberg CD. The impact of clinical trials on clinical practice. Arzneimittelforschung 1989; 39: 986-988.
6. Collet JP, Boissel JP and the VALIDATA Group. Sick population-treated population: the need for a better definition. Eur J Clin Pharmacol 1991; 41: 489-491.
7. Boissel JP. Note sur la nécessaire définition des objectifs thérapeutiques pour une démarche de prescription optimisée. Therapie 1996; 51: 287-289.
8. Kusmierek J. Du développement de la molécule à sa commercialisation. Revue du Praticien 1983; 33: 29-31.
9. Thénot A, Bachand R-T, Le Ridant A. La mort du médicament. Revue du Praticien 1983; 33: 32-30.
10. Yusuf S, Collins R, Peto R et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomised controlled trials. Eur Heart J 1985; 6: 536-585.
11. Amman EM, Lau J, Kulpenick B et al. A comparison of results of meta-analysis of randomized control trials and recommendations of clinical experts: Treatment of myocardial infarction. JAMA 1992; 268: 240-248.
12. Collins R, Julian D. British Heart Foundation survey (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. Br Heart J 1991; 66: 250-255.
13. Rosamond WD, Luepker RV, McGovern PG, Spralka JM. Recent trends of thrombolytic agent usages in clinical practice: a report from the Minnesota Heart Survey Registry. J Am Coll Cardiol 1992; 19: 20A.
14. Plotnick GD, Ziskind AA, Vogel RA. Survey of practicing physicians in Maryland on their choice of thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1992; 69:327-330.
15. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-894.
16. Ayanian JZ, Hauptman PJ, Guadagnoli E et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for myocardial infarction. N Engl J Med 1994; 331: 1136-1142.
17. Pashos CL, Normand SLT, Garfinkle JB et al. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994; 23: 1023-1030.
18. Fibrinolytic Therapy (FTP) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity events from all randomised trials of more than 1,000 patients. Lancet 1994; 345: 311-322.
19. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
20. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis; concepts and applications. Stockholm: Swedish Pharmaceutical Press, 1994.
21. IMPACT Research Group. International Mexiletine and Placebo Control Antiarhythmic Coronary Trial. J Am Coll Cardiol 1984; 4: 1148-1163.
22. The Cardiac Arrhythmia Suppression Trial (CAST). The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med 1989; 321: 386-391.
23. Lièvre M, Leizorovicz A, Boissel JP. Critères intermédiaires et critères de substitution dans le développement des antiarythmiques. Arch Mal Coeur 1991; 84: 27-33.
24. Hine LK, Laird NM, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term antiaarhythmic therapy after myocardial infarction. JAMA 1990; 262: 3037-3040.
25. Reimold SC, Chalmers TC, Berlin JA, Amman EM. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation-observations on the role of trial design and implications of drug related mortality. Am Heart J 1992; 124: 924-932.
26. Boissel JP, Collet JP, Lièvre M, Girard P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993; 22: 356-363.
27. Boissel JP, Peyrieux JC and the Epsim Research Group. Sub-grouping of post myocardial infarction patients according to their one-year death risk. Eur Heart J 1987; 8: 1272-1280.
28. Bossard N, Boissel JP. La hiérarchisation selon leur niveau de preuve des données sources, avant leur intégration dans une synthèse, en matière d'efficacité thérapeutique. Therapie 1996; 51: 261-264
29. Chalmers I, Dickersin K, Chalmers TC. Getting to grips with Archie Cochrane's agenda: all randomized controlled trials should be registered and reported. BMJ 1992; 305: 786-788.